"The data published today provide compelling evidence that molecular biomarkers used to determine lung cancer risk in cells from the bronchial airway could provide similar information as cells obtained from a simple nasal swab. This discovery could offer a method to further reduce the uncertainty, risk and cost associated with the early detection of lung cancer," said
The new findings build on research previously conducted by
In the current study,
After one year of follow up, researchers identified differentially expressed genes in the nasal epithelium of AEGIS-1 patients who were diagnosed with lung cancer vs. those with benign disease (p < 0.001). They also confirmed significant consistency between the field-of-injury alterations found in paired samples of cells from the lower and upper airways (i.e., bronchial and nasal epithelial cells).
Finally, the researchers determined that a non-invasive nasal classifier comprising 30 of the most differentially expressed genes significantly enhanced the ability of a risk model based only on clinical factors (e.g., age, smoking status) to predict lung-cancer status.
"The landmark findings published today reinforce the validity and clinical importance of the field-of-injury innovation underlying our Percepta Bronchial Genomic Classifier, which has already demonstrated the ability to reduce ambiguity in lung cancer diagnosis and thereby reduce the unnecessary, invasive and costly procedures that can result," said
The Veracyte Percepta classifier detects field of injury-associated genomic changes in cells collected by bronchoscopy, a minimally invasive procedure, to determine the likelihood that a lung nodule or lesion detected by CT scan is cancerous. In the AEGIS-1 and -2 studies, Percepta combined with bronchoscopy demonstrated a cancer-detection sensitivity of 97 percent as compared to 75 percent sensitivity for bronchoscopy alone. The test has demonstrated a high degree of accuracy (negative predictive value of 91 percent) in identifying patients at low ( < 10 percent) risk of cancer, allowing these patients to be monitored noninvasively with imaging and avoid further unnecessary, risky and costly invasive procedures.
Cautionary Note Regarding Forward-Looking Statement
This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "expect," "believe," "should," "may," "will" and similar references to future periods. Examples of forward-looking statements include, among others, our ability to successfully scale the company and our belief that we are well positioned for profitable growth. Forward-looking statements are neither historical facts nor assurances of future performance. Instead, they are based only on our current beliefs, expectations and assumptions regarding the future of our business, future plans and strategies, anticipated events and trends, the economy and other future conditions. Forward-looking statements involve risks and uncertainties, which could cause actual results to differ materially, and reported results should not be considered as an indication of future performance. These risks and uncertainties include, but are not limited to: the applicability of clinical results to actual outcomes; laws and regulations applicable to our business, including potential regulation by the Food and Drug Administration or other regulatory bodies; the size of the market opportunity for our products; our ability to successfully achieve adoption of and reimbursement for our products; the amount by which use of our products are able to reduce invasive procedures and misdiagnosis, and reduce healthcare costs; our products' ability to become the standard of care; the occurrence and outcomes of clinical studies; the timing and publication of clinical study results; and other risks set forth in the company's filings with the Securities and Exchange Commission, including the risks set forth in the company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2016. These forward-looking statements speak only as of the date hereof and Veracyte specifically disclaims any obligation to update these forward-looking statements.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/veracyte-announces-publication-of-data-demonstrating-potential-for-non-invasive-nasal-test-to-improve-lung-cancer-diagnosis-300413354.html
News Provided by Acquire Media